Global Health Investment Fund (GHIF)
GHIC is a nonprofit organization dedicated to investing in global health innovation, supporting biomedical innovations, and fostering partnerships to develop and commercialize health technologies that improve global health security, pandemic preparedness, and health equity. GHIC collaborates with government agencies, private investors, and international organizations to fund and support impactful health projects and companies worldwide.
Industries
Nr. of Employees
small (1-50)
Global Health Investment Fund (GHIF)
Products
Global Health Investment Fund (mission-aligned venture fund)
A mission-focused investment fund that targets products and technologies to improve global public health and health equity through equity investments and portfolio management.
Early-stage non-dilutive research funding program
A competitive funding mechanism supplying non-dilutive awards and fellowships to accelerate translational research for novel medical countermeasures.
Global Health Investment Fund (mission-aligned venture fund)
A mission-focused investment fund that targets products and technologies to improve global public health and health equity through equity investments and portfolio management.
Early-stage non-dilutive research funding program
A competitive funding mechanism supplying non-dilutive awards and fellowships to accelerate translational research for novel medical countermeasures.
Services
Direct equity investments and fund management to finance companies developing vaccines, therapeutics, diagnostics, medical devices, and manufacturing platforms relevant to global health security.
Short-term, non-dilutive awards and fellowships to accelerate early-stage translational research aimed at novel medical countermeasures and enabling technologies.
Operate long-term blended finance programs that combine grant, public and private capital to support health technologies and funds focused on low- and middle-income countries.
Coordinate technical analysis and objective evaluation of candidate technologies through strategic collaborations with independent technical organizations and research centers.
Direct equity investments and fund management to finance companies developing vaccines, therapeutics, diagnostics, medical devices, and manufacturing platforms relevant to global health security.
Short-term, non-dilutive awards and fellowships to accelerate early-stage translational research aimed at novel medical countermeasures and enabling technologies.
Operate long-term blended finance programs that combine grant, public and private capital to support health technologies and funds focused on low- and middle-income countries.
Coordinate technical analysis and objective evaluation of candidate technologies through strategic collaborations with independent technical organizations and research centers.
Expertise Areas
- Venture investing in medical countermeasures
- Public-private partnership management for health security
- Fund structuring and blended finance for LMIC health
- Biomanufacturing scale-up and commercial financing
Key Technologies
- Wearable biosensor platforms
- Microarray patch-based drug and vaccine delivery (dissolvable MAP)
- Computational protein design for biosensors
- Bioluminescent modular biosensors
News & Updates
GHIC launched a partnership with BARDA to accelerate development and commercialization of technologies for global public health emergencies, with BARDA providing initial funding and GHIC mobilizing private capital.
GHIC received its first BARDA funding installment of $10 million to invest in companies developing health security technologies, with plans for further investments supported by BARDA funding.
GHIC partnered with MITRE to evaluate and fund medical countermeasure technologies, leveraging MITRE’s technical expertise to expand investment activities in health security.
GHIC provided an anchor investment in the Women’s and Children’s Health Technology Fund, supporting health tech companies addressing women, children, and adolescents’ health needs.
GHIC received additional BARDA funding, totaling $21.6 million, to invest in health security companies, with plans for further investments supported by BARDA.
GHIC invested in Univercells, a biomanufacturing company, to support its growth in biologics production and global health impact.
GHIC launched a partnership with BARDA to accelerate development and commercialization of technologies for global public health emergencies, with BARDA providing initial funding and GHIC mobilizing private capital.
GHIC received its first BARDA funding installment of $10 million to invest in companies developing health security technologies, with plans for further investments supported by BARDA funding.
GHIC partnered with MITRE to evaluate and fund medical countermeasure technologies, leveraging MITRE’s technical expertise to expand investment activities in health security.
GHIC provided an anchor investment in the Women’s and Children’s Health Technology Fund, supporting health tech companies addressing women, children, and adolescents’ health needs.
GHIC received additional BARDA funding, totaling $21.6 million, to invest in health security companies, with plans for further investments supported by BARDA.
GHIC invested in Univercells, a biomanufacturing company, to support its growth in biologics production and global health impact.